Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing.  The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Nurses
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation Statement
Physicians
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
This 1 contact hour Educational Activity is provided by The Institute for Johns Hopkins Nursing. Each activity carries a maximum of 0.5 contact hours or a total of 2 contact hours for the six presentations in this program. To obtain contact hours, you must complete this Education Activity and post-test before
February 1, 2012.

Dieticians
The Johns Hopkins University has approved this activity for a maximum 2.0 contact hours for non-physicians.

Physical Therapists
The Johns Hopkins University has approved this activity for a maximum 2.0 contact hours for non-physicians.

Respiratory Therapists
For United States:
Click here to confirm that your state will accept the CE credits gained through this program.

For Canada:
Click here to confirm that your province will accept the CE credits gained through this program

Length of activity: 2.0 hours

Methods of participation in this activity can include viewing webcasts, listening to podcasts, or reading transcripts.  In addition, slides are available to be downloaded and printed.  The post-tests are the same for all delivery methods.

Post-Test
To take the post-test for Ahead of the Curve: Emerging CF Therapies 2009 you will need to visit The Johns Hopkins University School of Medicine's CME website, and The Institute for Johns Hopkins Nursing.   If you have already registered for another Hopkins CME program at this site, simply enter the requested information when prompted. Otherwise, complete the registration form to begin the testing process. A passing grade of 70% or higher on the post test/evaluation is required to receive CME credit.

Statement of Responsibility
The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing take responsibility for the content, quality and scientific integrity of this CME/CE activity.

Date of release: February 1, 2010
Expiration date: January 31, 2012

Intended Audience
This activity is intended for pulmonologists, pediatric pulmonologists, gastroenterologists, pediatricians, infectious disease specialists, respiratory therapists, dieticians, nutritionists, nurses, and physical therapists.  There are no prerequisites.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the most current understanding of the pathophysiology underlying CF
• Identify the potential therapeutic targets of current clinical research
• Summarize the known data regarding on-going research into CFTR modulators
• Recognize the current research regarding salt transport, correcting ion transport, P2Y2 agonists,
   ENaC antagonists, et al
• Integrate information about these emerging therapies into current clinical practice strategies for
   managing patient expectations

Internet CME Policy
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing are committed to protect the privacy of its members and customers. The Johns Hopkins University maintains its Internet site as an information resource and service for physicians, other health professionals and the public.

Continuing Medical Education at The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing will keep your personal and credit information confidential when you participate in a CE Internet-based program. Your information will never be given to anyone outside The Johns Hopkins University program. CE collects only the information necessary to provide you with the service you request.

Faculty Disclosure
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

John Paul Clancy, MD
Principle Investigator:  Cystic Fibrosis Foundation, Therapeutics, Inc., Inspire Pharmaceuticals,
Transave, Inc., Vertex Pharmaceuticals, Incorporated
Consultant: Transave, Inc., Vertex Pharmaceuticals, Incorporated

Christopher H. Goss, MD
Grants/Research Support: Transave, Inc.
Honorarium: Bayer

Peter Mogayzel, Jr., MD, PhD
Other Role: CF Director - Novartis Pharmaceuticals, Genentech, Inc.

Richard B. Moss, MD
Principle Investigator: Gilead, GlaxoSmithKline, Inspire Pharmaceuticals, PTC Therapeutics, Inc., Vertex Pharmaceuticals, Incorporated

Consultant: Aridis Pharmaceuticals, Arriva Pharmaceuticals, Inc., Genentech, Inc., Inspire Pharmaceuticals, Johnson & Johnson, Lantibio, Inc./AOP Orphan Pharmaceuticals AG, MPEX Pharmaceuticals, Novartis Pharmaceuticals, PTC Therapeutics, Inc., Vertex Pharmaceuticals, Incorporated

Dr. Moss has disclosed that his presentation will reference unlabeled/unapproved uses of drugs or products: Denufosol, mannitol, hypertonic saline, azithromycin, colistin, PTC124, VX770, VX809, TOBI

Stock Shareholder: Genentech, Inc., Gilead
Speaker Bureau: Novartis Pharmaceuticals, Genentech, Inc.

Meghan Ramsay, MS, CRNP
Discloses that she has no financial relationship with commercial supporters.

Pamela L. Zeitlin, MD, PhD
Principle Investigator: Cystic Fibrosis Foundation, Therapeutics, Inc., Food and Drug Administration, National Heart, Lung, and Blood Institute, Inspire Pharmaceuticals, Isis Pharmaceuticals, Inc., Pharmaxis, PTC Therapeutics, Inc., Vertex Pharmaceuticals, Incorporated

Stock Shareholder: Sucampo Pharmaceuticals, Inc.
Speaker Bureau: France Foundation

Dr. Zeitlin has disclosed that her presentation will reference unlabeled/unapproved uses of drugs or products: Amiloride, Bronchitol, cobiprostone, Denufosol, lubiprostone, mannitol, Moli1901

All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.

This program is supported by an educational grant from Vertex Pharmaceuticals, Incorporated

Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Copyright © JHUSOM, IJHN and Johns Hopkins Ahead of the Curve eSeminar Series